PureTech Health contemplating US listing on Nasdaq

Clinical-stage biopharmaceutical company PureTech Health announced that it was exploring the potential for a listing of American depository shares (ADS) on Nasdaq in the.

The London-listed firm said the ADSs would represent ordinary shares, and would be sold through a registered initial public offering in the US.

It said the US listing would be expected to include an issue of new ordinary shares underlying the ADSs.

The terms of any US listing had not yet been determined, the board said, adding that there could be no assurance as to the timing or completion of any US listing.

“The company intends that the potential US listing would be in addition to the company's premium listing on the Official List of the UK Financial Conduct Authority and trading on the main market of the London Stock Exchange,” PureTech Health explained in its statement.

“A further announcement will be made by PureTech if and when appropriate.”